Evidence mapPaperPMID 41315372Full record

ArticleScientific reports2025

Household exposure, demographic and health characteristics associated with SARS-CoV-2 infection in a cohort study in Northern France.

Simon Galmiche, Laurie Pinaud, Laura Tondeur, Stephane Pelleau, Mikaël Attia, Sandrine Castelain, Isabelle Staropoli, Cécile Duru, Aymar Davy Koffi, Sandrine Fernandes-Pellerin and 6 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Simon GalmicheEmerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, Paris, France. simon.galmiche@mail.mcgill.ca.
Laurie Pinaud *Emerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, Paris, France.
Laura Tondeur *Emerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, Paris, France.
Stephane PelleauInfectious Diseases Epidemiology and Analysis G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Inserm U1347, Paris, France.
Mikaël AttiaMolecular Genetics of RNA Viruses Unit, Department of Virology, Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Paris, France.
Sandrine CastelainDepartment of Virology, Amiens University Medical Center, Amiens, France.
Isabelle StaropoliVirus and Immunity Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Cécile DuruHôpital de Crépy-en-Valois, Crépy-en-Valois, France.
Aymar Davy KoffiHôpital de Crépy-en-Valois, Crépy-en-Valois, France.
Sandrine Fernandes-PellerinPôle de Coordination de la Recherche Clinique (PC-RC), Institut Pasteur, Université Paris-Cité, Paris, France.
Nathalie JollyPôle de Coordination de la Recherche Clinique (PC-RC), Institut Pasteur, Université Paris-Cité, Paris, France.
Emmanuel RouxBiobanque de Collections de Ressources Biologiques d'Origine Humaine (ICAReB-Biobank), Center for Translational Science, Institut Pasteur, Université Paris Cité, Paris, France.
Olivier SchwartzVirus and Immunity Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Sylvie van der WerfMolecular Genetics of RNA Viruses Unit, Department of Virology, Institut Pasteur, Université Paris Cité, CNRS UMR 3569, Paris, France.
Michael WhiteInfectious Diseases Epidemiology and Analysis G5 Unit, Department of Global Health, Institut Pasteur, Université Paris-Cité, Inserm U1347, Paris, France.
Arnaud FontanetEmerging Diseases Epidemiology Unit, Department of Global Health, Institut Pasteur, Université Paris Cité, Paris, France.

Funding

Agence Nationale de la Recherche ANR-10-LABX-62-IBEIDAgence Nationale de la Recherche PIA/ANR-16-CONV-0005European Commission DURABLE grant 101102733European Commission RECOVER 101003589Institut Pasteur URGENCE COVID-19Vaccine research institute ANR-10-LABX-77
6 · The paper itself

Abstract

In this cohort study, we aimed to study the risk of SARS-CoV-2 infection and its association with household exposure, as well as demographic and health factors. Between March 2020 and April 2022, we conducted a cohort study among adults and children aged 5 years or more in a town in northern France. Participants were screened repeatedly for post-infection anti-SARS-CoV-2 immunity. Infection dates were inferred in hierarchical order from symptomatic episodes or virological tests, or if unavailable from the timing of other cases in the household or the window of seroconversion. Household exposure to a case of SARS-CoV-2 during the infectious phase was defined as a time-varying exposure. We included 830 participants with a mean follow-up of 453 days (12,353 total person-months), during which we identified 491 infections (incidence rate 39.7 per 1,000 person-months). In adjusted analyses, exposure in the household to an infected individual was associated with an incidence rate ratio (IRR) of 16.48 (95% CI 12.29-22.09), and baseline statin use was associated with a decreased risk of infection (IRR 0.35, 95% CI 0.13-0.89). These results could contribute to the development of additional prophylactic strategies, e.g., post-exposure, for the population at high risk of severe forms of COVID-19.

Indexed as

COVID-19SARS-CoV-2AdolescentAdultAgedChildChild, PreschoolCohort StudiesFamily CharacteristicsFemaleFranceHumansIncidenceMaleMiddle AgedRisk Factors

Identifiers

PMID41315372
PMCPMC12663452

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.